Expression of Urokinase and Its Receptor in Invasive and Non-Invasive Prostate Cancer Cell Lines

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Thrombosis and Haemostasis

• Publication date

  1992-12-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1055/s-0038-1646340PMID 1337629
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene.

  1991cited by this paper
• Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.

  1991cited by this paper
• Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.

  1991cited by this paper
• Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases.

  1990cited by this paper
• Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

  1990cited by this paper
• Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA.

  1990cited by this paper
• The role of urokinase-type plasminogen activator in aggressive tumor cell behavior

  1990cited by this paper
• Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.

  1990cited by this paper
• Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.

  1989cited by this paper
• Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.

  1989cited by this paper
• Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes.

  1989cited by this paper
• In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase

  1988cited by this paper
• A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.

  1988cited by this paper
• The Receptor-Binding Sequence of Urokinase

  1987cited by this paper
• The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.

  1987cited by this paper
• Autocrine saturation of pro-urokinase receptors on human A431 cells.

  1986cited by this paper
• Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

  1985cited by this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cited by this paper
• Primary structure of single-chain pro-urokinase.

  1985cited by this paper
• The human urokinase-plasminogen activator gene and its promoter.

  1985cited by this paper
• A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

  1985cited by this paper
• Plasminogen activation and regulation of pericellular proteolysis.

  1985cited by this paper
• Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA.

  1984cited by this paper
• Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.

  1984cited by this paper
• Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.

  1981cited by this paper
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979cited by this paper
• The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin.

  1967cited by this paper

• Prostate cancer as a multifactorial disorder: an overview of the different sides of disease

  2021cites this paper
• The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.

  2015cites this paper
• Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.

  2013cites this paper
• Urokinase receptor expression involves tyrosine phosphorylation of phosphoglycerate kinase

  2010cites this paper
• System in Tumor Invasion

  2010cites this paper
• Investigational Angiogenesis Inhibitors

  2010cites this paper
• Selective Growth Inhibition of Cancer Cells by L-Methioninase-Containing Fusion Protein Targeted to the Urokinase Receptor

  2009cites this paper
• Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.

  2007cites this paper
• Advances in Brief Inhibitors of Urokinase Reduce Size of Prostate Cancer Xenografts in Severe Combined Immunodeficient Mice '

  2006cites this paper
• Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors

  2006cites this paper
• Internalizing Versus Non-internalizing Receptors for Targeting L-Methioninase to Cancer Cells

  2006cites this paper
• Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells

  2005cites this paper
• A novel function of differentiation revealed by cDNA microarray profiling of p75NTR-regulated gene expression.

  2005cites this paper
• Molecular profile of androgen-independent prostate cancer xenograft LuCaP 23.1.

  2005cites this paper
• Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.

  2005cites this paper
• Spinal cord compression in prostate cancer

  2005cites this paper
• Expression of urokinase plasminogen activator, its receptor and type‐1 inhibitor in malignant and benign prostate tissue

  2005cites this paper
• Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells

  2005cites this paper
• MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription.

  2004cites this paper
• Urokinase receptor mRNA stability involves tyrosine phosphorylation in lung epithelial cells.

  2004cites this paper
• The Urokinase-type Plasminogen Activator System in Prostate Cancer Metastasis

  2004cites this paper
• Regulation of urokinase receptor expression by phosphoglycerate kinase.

  2004cites this paper
• Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis

  2004cites this paper
• A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.

  2003cites this paper
• Role of Coagulation and Fibrinolytic System in Prostate Cancer

  2003cites this paper
• Formation of Polyomavirus-Like Particles with Different VP1 Molecules That Bind the Urokinase Plasminogen Activator Receptor

  2003influential citation
• Role of coagulation and fibrinolytic system in prostate cancer.

  2003cites this paper
• Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue

  2003cites this paper
• Amplification and Overexpression of Elongin C Gene Discovered in Prostate Cancer by cDNA Microarrays

  2002cites this paper
• Urokinase induces its own expression in Beas2B lung epithelial cells.

  2002cites this paper
• Human retinal pigment epithelial lysis of extracellular matrix: functional urokinase plasminogen activator receptor, collagenase, and elastase.

  2002cites this paper
• Urokinase Induces Expression of Its Own Receptor in Beas2B Lung Epithelial Cells*

  2001cites this paper
• Advances in Brief Amplification of Urokinase Gene in Prostate Cancer 1

  2001cites this paper
• Regulation of u‐PA gene expression in human prostate cancer

  2001cites this paper
• Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer

  2001cites this paper
• Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.

  2001cites this paper
• Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer.

  2001cites this paper
• Assembly of the Plasminogen System on Cell Surfaces

  2001cites this paper
• Amplification of urokinase gene in prostate cancer.

  2001cites this paper
• Accelerated Tumor Cell Death by Angiogenic Modifiers

  2001cites this paper
• Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro.

  2000cites this paper
• Recombinant Toxins That Bind to the Urokinase Receptor Are Cytotoxic without Requiring Binding to the α2-Macroglobulin Receptor*

  2000cites this paper
• Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro

  1999cites this paper
• The Role of the Plasminogen Activation System in Cancer

  1999cites this paper
• Plasminogen and cell migration in vivo

  1999cites this paper
• The interaction of plasminogen with the cell surface: involvement of plasminogen binding and activation during cell death

  1999cites this paper
• Androgen induction of urokinase gene expression in LNCaP cells is dependent on their interaction with the extracellular matrix.

  1998cites this paper
• In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.

  1998cites this paper
• Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.

  1997cites this paper
• Thrombin stimulates expression of the receptor for urokinase-type plasminogen activator in DU-145 prostate cancer cells

  1997cites this paper
• Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.

  1997cites this paper
• The Fibrinolytic System in Neoplasia

  1996cites this paper
• Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma

  1996cites this paper
• Invasion and metastasis

  1996cites this paper
• Fibroblast growth factor 2 and the protease activity of tumor cells isolated from BK virus/tat transgenic mice

  1996cites this paper
• Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.

  1996cites this paper
• Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines

  1995cites this paper
• Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas

  1995cites this paper
• The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae

  1995cites this paper
• Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

  1995cites this paper
• Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.

  1995cites this paper
• Transcriptional activation of the urokinase receptor gene in invasive colon cancer

  1994cites this paper
• Plasminogen-plasmin System in Tumor Invasion

  1994cites this paper
• Regulation of urokinase‐type plasminogen activator expression in squamous‐cell carcinoma of the oral cavity

  1993cites this paper